A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

More documents

Recommendations

Info

FinkeLancet Oncol 2009;10: 855–64BacigalupoBlood 2001;98:2942BBMT 2006;12:560ATG-Fresenius60 mg/kg totalThymoglobulinLow-dose7.5 mg/kg totalThymoglobulinHigh-dose15 mg/kg totalPrimary End-Point Death/AGVHD III-IV AGVHD III-IVPrimary End-Point NS NS 11% vs 50%, P=.001Infectious Deaths NS NS 30% vs 7%Survival NS NS NSNon RelapseMortalityChronic GVHD 30.8% vs 58.8%p
The Primary EndpointFreedom of chronic graft versus host disease at 12 months fromtransplantation defined as withdrawal of all systemicimmunosuppressive agents without resumption up to 12 monthsafter transplantation (this end-point is binary i.e. Yes/No).
Page 1 and 2: A Randomized Trial of Thymoglobulin
Page 3 and 4: Appendix AIllustrations of cGVHD -
Page 5: Quality of LifeFraser CJ et al. Imp
Page 12 and 13: A Randomized Trial of Thymoglobulin
Page 14 and 15: FundingTOTAL GRANT:CIHR:$1,245,055
Page 18 and 19: Time to Onset of Prednisone RxMielk
Page 20 and 21: Secondary End-Points• Time to eng
Page 22 and 23: Treatment Plan - ThymoglobulinThe e
Page 24 and 25: Flu-Bu-ATG (Slavin) vs F-TBI (Seatt
Page 26 and 27: Benefits and Harms• BENEFITS• L
Page 28 and 29: PTLD in Unrelated/Mismatch +ATGStud
Page 30 and 31: Performance of QPCR test for EBVAss
Page 32 and 33: cGVHD Manifestions - NIHFilipovich
Page 34 and 35: cGVHD Case Report Form (CRF)
Page 36 and 37: cGVHD Case Report Form (CRF)
Page 38 and 39: Body Surface Area (Rule of 9)
Page 40 and 41: Will CBMTG 0801 succeed?In part for
Page 42 and 43: Flowers ME, Storer BE, Lee SJ, et a
Page 44: Thank you

A Randomized Trial of Thymoglobulin to Prevent Chronic ... - CBMTG

Create successful ePaper yourself

Delete template?

Save as template?